AT502722B8 - Verwendung des interferon induzierten gens 12 (isg 12, ifi 27) zur modulation transkriptioneller aktivitäten von nuklearen rezeptoren - Google Patents

Verwendung des interferon induzierten gens 12 (isg 12, ifi 27) zur modulation transkriptioneller aktivitäten von nuklearen rezeptoren Download PDF

Info

Publication number
AT502722B8
AT502722B8 AT0179005A AT17902005A AT502722B8 AT 502722 B8 AT502722 B8 AT 502722B8 AT 0179005 A AT0179005 A AT 0179005A AT 17902005 A AT17902005 A AT 17902005A AT 502722 B8 AT502722 B8 AT 502722B8
Authority
AT
Austria
Prior art keywords
interferone
isg
ifi
nuclear receptors
induced gene
Prior art date
Application number
AT0179005A
Other languages
English (en)
Other versions
AT502722B1 (de
AT502722A1 (de
Original Assignee
Bmt Medizinische Forschung Und
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bmt Medizinische Forschung Und filed Critical Bmt Medizinische Forschung Und
Priority to AT0179005A priority Critical patent/AT502722B8/de
Priority to EP06804375A priority patent/EP1945805A2/de
Priority to PCT/AT2006/000448 priority patent/WO2007051218A2/de
Priority to US12/092,189 priority patent/US20080313751A1/en
Publication of AT502722A1 publication Critical patent/AT502722A1/de
Publication of AT502722B1 publication Critical patent/AT502722B1/de
Application granted granted Critical
Publication of AT502722B8 publication Critical patent/AT502722B8/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT0179005A 2005-10-31 2005-10-31 Verwendung des interferon induzierten gens 12 (isg 12, ifi 27) zur modulation transkriptioneller aktivitäten von nuklearen rezeptoren AT502722B8 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AT0179005A AT502722B8 (de) 2005-10-31 2005-10-31 Verwendung des interferon induzierten gens 12 (isg 12, ifi 27) zur modulation transkriptioneller aktivitäten von nuklearen rezeptoren
EP06804375A EP1945805A2 (de) 2005-10-31 2006-10-31 Verfahren unter verwendung von humanem oder mäuse-isg12 zur entwicklung und herstellung von medikamenten sowie von single-nucleotide-polymorphismus im isg12-gen zu diagnosezwecken
PCT/AT2006/000448 WO2007051218A2 (de) 2005-10-31 2006-10-31 Verfahren unter verwendung von humanem oder mäuse-isg12 zur entwicklung und herstellung von medikamenten sowie von single-nucleotide-polymorphismus im isg12-gen zu diagnosezwecken
US12/092,189 US20080313751A1 (en) 2005-10-31 2006-10-31 Method by Using Human or Mice-Isg12 to Develop and Prepare Drugs and Single Nucleotide Polymorphism in the Isg12 Gene for Diagnostic Use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0179005A AT502722B8 (de) 2005-10-31 2005-10-31 Verwendung des interferon induzierten gens 12 (isg 12, ifi 27) zur modulation transkriptioneller aktivitäten von nuklearen rezeptoren

Publications (3)

Publication Number Publication Date
AT502722A1 AT502722A1 (de) 2007-05-15
AT502722B1 AT502722B1 (de) 2009-07-15
AT502722B8 true AT502722B8 (de) 2009-08-15

Family

ID=38006218

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0179005A AT502722B8 (de) 2005-10-31 2005-10-31 Verwendung des interferon induzierten gens 12 (isg 12, ifi 27) zur modulation transkriptioneller aktivitäten von nuklearen rezeptoren

Country Status (4)

Country Link
US (1) US20080313751A1 (de)
EP (1) EP1945805A2 (de)
AT (1) AT502722B8 (de)
WO (1) WO2007051218A2 (de)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000087A2 (en) * 2003-06-03 2005-01-06 Chiron Corporation Gene products differentially expressed in cancerous colon cells and their methods of use ii
US20020137081A1 (en) * 2001-01-08 2002-09-26 Olga Bandman Genes differentially expressed in vascular tissue activation
US6681543B2 (en) * 2001-03-28 2004-01-27 Toyoda Gosei Co., Ltd. Vehicle molding and method for attaching the vehicle molding
DE60326931D1 (de) * 2002-01-08 2009-05-14 Novartis Vaccines & Diagnostic In kanzerösen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren
WO2004011618A2 (en) * 2002-07-29 2004-02-05 Hmgene, Inc. Methods of identifying adipocyte specific genes, the genes identified, and their uses
CN102220423A (zh) * 2002-08-20 2011-10-19 千年药品公司 用于鉴定,评估,预防和治疗子宫颈癌的组合物,试剂盒及方法
US20050009067A1 (en) * 2003-05-19 2005-01-13 Craig Logsdon Expression profile of pancreatic cancer
JP2005204549A (ja) * 2004-01-21 2005-08-04 Hubit Genomix Inc Ｃ型肝炎ウイルス感染者の経過に関する遺伝子およびその利用

Also Published As

Publication number Publication date
US20080313751A1 (en) 2008-12-18
AT502722B1 (de) 2009-07-15
WO2007051218A3 (de) 2007-09-20
EP1945805A2 (de) 2008-07-23
WO2007051218A2 (de) 2007-05-10
AT502722A1 (de) 2007-05-15

Similar Documents

Publication Publication Date Title
EA200700702A1 (ru) Аналоги локсапина и способы их применения
FR20C1033I1 (fr) Anticorps anti-cd79b, immuno-conjugues et procedes d'utilisation
ATE448234T1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung
ATE513833T1 (de) Thienopyridinverbindungen und verfahren zu ihrer verwendung
WO2006049734A3 (en) Quetiapine analogs and methods of use thereof
ATE388635T1 (de) Verwendung von menadione zur verstärkung der wirksamkeit von agrochemikalien
ATE381334T1 (de) 2,5-substituiertetetrahydroisochinoline zur verwendung als 5-ht6 modulatoren
DE502005006286D1 (de) Verwendung von trisubstituierten benzopyranonen
TW200716624A (en) Compounds for modulating TRPV3 function
EA200901653A1 (ru) ОПОСРЕДУЕМОЕ PHKi ИНГИБИРОВАНИЕ ЭКСПРЕССИИ АЛЬФА-EnaC
DE602005002836D1 (de) Diagnoseverfahren für erkrankungen unter verwendung von copeptin
BR112013005116A2 (pt) moduladores e métodos de uso
DK2173730T3 (da) Hidtil ukendte forbindelser 951: biphenyloxypropansyre som crth2-modulator og mellemprodukter
ATE512141T1 (de) Verwendung von tetrahydrobenzoxazinen als antioxidantien
DE602007008222D1 (de) Diazepanderivate als modulatoren von chemokinrezeptoren
DE112005000151A5 (de) Verwendung von Kern-Mantel-Partikeln
DE502005008502D1 (de) Vorrichtung zur veränderung der steuerzeiten von g
DE602005018156D1 (de) Methode zur Intensivierung der Haarfarbe
BRPI0910548A2 (pt) método e aparelho para ligar esquema de modulação codificada à quantidade de recursos.
ATE486878T1 (de) Benzothienopyridine zur verwendung als inhibitoren von eg5-kinesin
ATE510556T1 (de) Verwendung von erythropoietin
ATE495243T1 (de) Verfahren zur herstellung von hochempfindlichen endonukleasen, neuartige zubereitungen von nukleasen und ihre verwendung
ATE522221T1 (de) Verwendung von chitosanen zum erhöhen der nagelwachstumsrate
EA200700648A1 (ru) 4-((феноксиалкил)тио)феноксиуксусные кислоты и аналоги
DE602006016863D1 (de) Zufuhr von teilchenförmigem material zu einer verdampfungszone

Legal Events

Date Code Title Description
EIH Change in the person of patent owner
MM01 Lapse because of not paying annual fees

Effective date: 20131031